Last reviewed · How we verify
Remimazolam Tosilate for Injection
Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis.
Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis. Used for Procedural sedation and anesthesia induction, Sedation in intensive care units.
At a glance
| Generic name | Remimazolam Tosilate for Injection |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation |
| Phase | FDA-approved |
Mechanism of action
Remimazolam tosilate is a rapid-onset, short-acting benzodiazepine agonist at GABA-A receptors in the central nervous system. It potentiates inhibitory GABAergic signaling, leading to sedative, anxiolytic, and muscle-relaxant effects. The drug is rapidly metabolized by tissue esterases, resulting in a shorter duration of action compared to traditional benzodiazepines.
Approved indications
- Procedural sedation and anesthesia induction
- Sedation in intensive care units
Common side effects
- Hypotension
- Respiratory depression
- Headache
- Nausea
- Injection site pain
Key clinical trials
- A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients (PHASE2, PHASE3)
- A Study of Remimazolam Tosilate for Sedation in the ICU (PHASE3)
- A Non-intervention Fiberoptic Bronchoscopy Study of Remazolam Toluene Sulfonate for Injection Under General Anesthesia and Fiberoptic Bronchoscopy
- A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
- A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU (PHASE1, PHASE2)
- Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults (PHASE4)
- A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures (PHASE4)
- A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: